Unichem Laboratories gets USFDA nod for Metronidazole tablets

Unichem Laboratories has received approval from the US Food & Drug Administration to sell

RELATED ARTICLES

generic Metronidazole tablets, an anti-infective agent, in the American market.

The approval is for Metronidazole in strengths of 250 mg and 500 mg, which are therapeutically equivalent to Flagyl Tablets of corresponding strengths of GD Searle LLC, the company said in a filing to the BSE.

The drug is an anti-infective agent used to treat a variety of bacterial and protozoal infections.

The product will be commercialised from Unichem's Ghaziabad plant. Active pharmaceutical ingredient Metronidazole used for this ANDA is also made in-house at Roha plant, it said.

At present, around six other companies have generic approvals for the US market and the estimated market size is over $100 million, the company added.

Shares of Unichem Laboratories were trading at Rs 216 per scrip in the afternoon trade, up 0.87 per cent from the previous close, on the BSE.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • With RBI’s role diluted, we are moving closer towards a super regulator

    The government and the Reserve Bank of India (RBI) have signed a monetary policy framework agreement last month under which RBI will be committed to b

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Roopen Roy

The making of a digital Bharat

Exactly 20 years ago, Nicholas Negroponte of MIT Media Labs ...

Rajgopal Nidamboor

The eternal radiance of our being

We sense, we sight, we smell, we touch, we hear, ...

Shona Adhikari

Art world celebrates two ‘new’ Cezannes

The focus moves once more to post-impressionist Paul Cezanne, who ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture